DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer

Clinical Epigenetics

Table 1 Resistant cell lines

Parental cell line	RRID	Origin	Therapy drug	Parental IC₅₀	Therapy target	Exposure period	Resistant cell line	Resistant IC₅₀	EMT	Ref
HepG2 (n = 2)	CVCL_0027	Liver	Sorafenib	0.28 μM	VEGFR, PDGFR, Raf kinases	6–12 months	HepG2S1	0.44 μM	Full	[16]
HepG2 (n = 2)	CVCL_0027	Liver	Sorafenib	0.28 μM	VEGFR, PDGFR, Raf kinases	6–12 months	HepG2S3	0.69 μM	Full	[16]
HCC4006P1	CVCL_1269	Lung	Erlotinib	0.03 μM	EGFR	3–6 months	HCC4006ER	0.97 μM	Full	[17]
Panc 03.27 (‘PancVB’) (n = 2)	CVCL_1635	Pancreas	5-Fluorouracil	14.63 μM	Thymidylate synthase	6 months	PancB1Q	55.72 μM	Full	[18]
Panc 03.27 (‘PancVB’) (n = 2)	CVCL_1635	Pancreas	5-Fluorouracil	14.63 μM	Thymidylate synthase	6 months	PancB1V	30.75 μM	Full	[18]
HCC4006P2	CVCL_1269	Lung	Gefitinib	0.10 μM	EGFR	3 months	HCC4006GR	0.59 μM	Full	[19]
HCC827P	CVCL_2063	Lung	Gefitinib	0.027 μM	EGFR	3 months	HCC827GR	0.046 μM	Full	[19]
UWB 1.289 (n = 2)	CVCL_B079	Ovary	Olaparib	58.02 μM	PARP	5 months	U10	512.33 μM	Partial	[20]
UWB 1.289 (n = 2)	CVCL_B079	Ovary	Olaparib	58.02 μM	PARP	5 months	U100	699.41 μM	Partial	[20]
IGROV-1	CVCL_1304	Ovary	Cisplatin	64.04 μM	DNA replication	9 months	IGROV-1/CDDP	388.02 μM	Partial	[21]

The columns indicate which established cell line was used as the parental cell line, their Research Resource Identifiers (RRID), their tissue of origin, the drug they were made resistant to, the concentration of the drugs at which their growth was inhibited by 50% (IC₅₀), the target of the drug, the period over which they were rendered resistant, the name of their resistant counterparts, the concentration of drugs at which the growth of the resistant cells was inhibited by 50% (IC₅₀), their EMT status and the reference of the paper describing their retrieval

ISSN: 1868-7083